News

Eli Lilly and Maryland-based MacroGenics have declared that the Protege trial has achieved its targeted patient enrollment. The Protege trial is a randomized, double-blind, multi-center, multi-national, 4-arm, controlled

Matrixx Initiatives has confirmed that it has received a warning letter from FDA about two of its 19 existing Zicam products – Zicam Cold Remedy Nasal Gel and

Abbott has announced the initiation of Spirit Prime, a clinical trial to study the performance of the next-generation Xience Prime Everolimus Eluting Coronary Stent System, for the treatment

Switzerland-based Lonza and US-based Elusys have entered into an agreement to produce Anthim. Anthim is a therapeutic monoclonal antibody in late stage of development for the treatment of

CeNeRx has announced the completion of $9 million financing. The financing includes a $5 million credit facility from MidCap Financial, and an additional $4 million invested by current

Pennsylvania-based Three Rivers Pharmaceuticals has announced positive results from phase-III direct trial of once-daily Infergen with Ribavirin in Hepatitis C virus treatment failures. Among participants who failed initial

Genzyme has detected a virus that impairs cell growth in one of six bioreactors at Allston Landing manufacturing facility. So, the company has decided to temporarily stop bulk

Molecular Insight has presented clinical data on prostate cancer diagnostic at the 2009 annual meeting of the Society of Nuclear Medicine (SNM) in Toronto. The clinical data was

Nuvo has entered into a license and development agreement with Covidien, to market and sell Pennsaid, and its follow-on product, Pennsaid Plus, in the US. Under the agreement,